Business
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally Diarrhea is ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally","length":238,"tagName":"p"},{"type":"text","content":"Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs","length":248,"tagName":"p"},{"type":"text","content":"Jaguar CEO Lisa Conte presenting July 17 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register","length":136,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / July 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that four dogs have now been enrolled in Jaguar's ongoing field study of Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, and enrollment is continuing. Six veterinary oncology clinics have signed on to take part in this study, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation.","length":645,"tagName":"p"},{"type":"text","content":""Jaguar's primary objective for Canalevia (crofelemer delayed-release tablets) is to identify a partner with which to collaborate to achieve our three parallel goals for the drug: Obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs; and to expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs," said Lisa Conte, Jaguar's Founder and CEO. "I'm pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally."","length":799,"tagName":"p"},{"type":"text","content":"Canalevia contains crofe...